Stability of low molecular weight heparin anti-factor Xa activity in citrated whole blood and plasma

被引：9
|
作者：
Birri, Nicole [1 ]
Baumgartner, Daniela
Conte, Tiziana
Huynh, Anh
Weller, Katja
Pavicic, Marko
Reusser, Marianne
Siegenthaler, Ilse
Barizzi, Gabriela
Alberio, Lorenzo
机构：
[1] Univ Hosp Bern, Inselspital, Dept Haematol, CH-3010 Bern, Switzerland
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2011年 / 155卷 / 05期
关键词：
anticoagulation; heparin; laboratory haematology; PLATELET FACTOR-4; ASSAYS;
D O I：
10.1111/j.1365-2141.2011.08745.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：629 / 631
页数：4
相关论文
共 50 条
  • [31] Chemoenzymatic Synthesis of Heparin Oligosaccharides with both Anti-factor Xa and Anti-factor IIa Activities
    Xu, Yongmei
    Pempe, Elizabeth H.
    Liu, Jian
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (34) : 29054 - 29061
  • [32] Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children
    Wysocki, Emma L.
    Kuhn, Alexis
    Steinbrenner, Jenny
    Tyrrell, Laura
    Abdel-Rasoul, Mahmoud
    Dunn, Amy
    Cloyd, Colleen
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (07) : E946 - E950
  • [33] ANTI-FACTOR XA DETERMINATION IN BLOOD - A NEW METHOD FOR CONTROLLING HEPARIN-THERAPY
    HARENBERG, J
    HAAF, B
    SCHAFER, M
    DEMPFLE, CE
    STEHLE, G
    HEENE, DL
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1993, 19 : 79 - 85
  • [34] Low molecular weight heparin is responsible for the anti-Xa activity of desmin 370
    Brieger, D
    Dawes, J
    [J]. THROMBOSIS AND HAEMOSTASIS, 1996, 75 (02) : 286 - 291
  • [35] Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol
    Williams-Norwood, Tanya
    Caswell, Megan
    Milner, Barbara
    Vescera, Joseph C.
    Prymicz, Kelly
    Ciszak, Amy G.
    Ingle, Carol
    Lacey, Christopher
    Stavrou, Evi X.
    [J]. AACN ADVANCED CRITICAL CARE, 2020, 31 (02) : 129 - 137
  • [36] Validation of a weight based heparin nomogram that utilizes anti-factor Xa levels for monitoring.
    Huh, Jin-Hyeun
    Leong, Derek
    Lau, Maxine
    Gavrilovic, Maja
    [J]. BLOOD, 2006, 108 (11) : 108B - 108B
  • [37] Monitoring Unfractionated Heparin Treatments. Stability of Plasma Anti-Xa Activity up to 4 Hours in Citrated Tubes
    Appert-Flory, Anny
    Fischer, Florence
    Jambou, Didier
    Buvat, Sylvain
    Mahagne, Marie-Helene
    Toulon, Pierre
    [J]. BLOOD, 2019, 134
  • [38] Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin
    Jara-Palomares, Luis
    Marin-Romero, Samira
    Isabel Asensio-Cruz, Maria
    Elias-Hernandez, Teresa
    Ortega-Rivera, Rocio
    Otero-Candelera, Remedios
    Montero-Romero, Emilio
    Tallon-Aguilar, Rodrigo
    Dolores Ucero-Leon, Maria
    Arellano-Ceballos, Manuel
    Ruiz-Serrano De La Espada, Maria Rosario
    Fernandez-Garcia, Candido
    Maria Sanchez-Diaz, Jose
    Sanchez-Lopez, Veronica
    Arellano-Orden, Elena
    Ferrer-Galvan, Marta
    Barco, Stefano
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [39] Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (Enoxaparin)
    PerezRequejo, JL
    LucenaSolano, O
    PerezGarcia, M
    Santarelli, MT
    [J]. THROMBOSIS AND HAEMOSTASIS, 1997, : P1172 - P1172
  • [40] Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (enoxaparin)
    PerezRequejo, JL
    LucenaSolano, O
    PerezGarcia, M
    Santarelli, MT
    [J]. THROMBOSIS RESEARCH, 1997, 85 (03) : 259 - 265
12345